Amgen's anti-IL-17R mAb meets psoriasis endpoint

Amgen Inc. (NASDAQ:AMGN) said all doses of brodalumab (formerly AMG 827) met the primary endpoint of a greater percentage improvement in Psoriasis Area and Severity Index score from baseline to week 12 vs. placebo in a Phase II trial to treat psoriasis. Specifically, 70, 140, 210 and 280 mg subcutaneous doses of the mAb against IL-17R led to improvements in PASI score from baseline of 45%, 85.9%, 86.3% and 76%, respectively, vs. 16% for placebo (p<0.001 for all). The double-blind, international trial enrolled 198 patients with moderate to severe plaque psoriasis. ...